Loading…
Curis Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -100.0% over 5Y.
today you would have $0.26▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $19.80 | $61.20 | $255.00 | $220.00 | $1,904.00 | $3,276.00 | $680.00 | $276.00 | $1,400.00 | $6,160.00 | $5,820.00 | $3,000.00 | $5,640.00 | $6,860.00 | $9,360.00 | $3,960.00 | $6,500.00 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RNAZTranscode Therapeutics, Inc. | $2.18 | — | 1.6x | — | -59.28% | $2.31M |
| OGENOragenics Inc | $0.52 | 0.5x | 0.4x | — | -1307.06% | $2.37M |
| VRAXVirax Biolabs Group Ltd | $2.82 | — | 0.2x | — | -78.65% | $2.25M |
| ONCOOnconetix, Inc. | $0.61 |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Company description provided by Yahoo Finance.
| P/E | — | — | — | — | — | 190.4x | — | — | — | — | — | — | — | — | — | — | — | — |
| P/S | 274.4x | 4.2x | 2.4x | 7.5x | 104.6x | 819.3x | 1383.4x | 124.3x | 43.9x | 234.3x | 1161.2x | 953.2x | 314.5x | 323.1x | 323.8x | 491.5x | 187.5x | — |
| P/B | 103.9x | 7.2x | — | 3.8x | 22.8x | 96.2x | 114.7x | — | — | 96.6x | 296.8x | 116.4x | 103.9x | 107.3x | 160.4x | 181.9x | 65.9x | — |
| EPS | -$11.60 | -$137.60 | -$179.20 | -$242.80 | $10.00 | -$12.20 | -$19.40 | -$19.60 | -$35.80 | -$45.00 | -$48.00 | -$22.00 | -$15.00 | -$21.00 | -$13.00 | -$6.00 | -$15.00 |
| Profit margin | -312.38% | -80.29% | -397.77% | -473.04% | -557.69% | -426.67% | -276.03% | -321.28% | -312.38% | -538.66% | -802.59% | -748.68% | -190.28% | -82.14% | -96.73% | -66.78% | -27.72% | -114.35% |
| ROE | -56.49% | -138.81% | — | -241.04% | -121.74% | -50.09% | -22.89% | — | — | -222.22% | -205.12% | -91.43% | -62.88% | -27.28% | -47.91% | -24.72% | -9.74% | -29.72% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 0.0x |
| 0.2x |
| — |
| -105.23% |
| $2.42M |
| IVFINVO Fertility, Inc. | $1.00 | 0.0x | 0.1x | — | -55.28% | $2.51M |
| AKANAkanda Corp | $3.89 | — | — | — | — | $2.1M |